Subscribe to RSS
You must select a month AND year to filter.
Practice
-
ASH Awards First Bridge Grants to Sustain Critical Hematology Research During Current Period of Funding Restrictions
-
April 8, 2013
-
The American Society of Hematology (ASH), the world’s largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health (NIH). The announcement coincides with the Society’s participation as a Platinum Supporter in the “Rally for Medical Research,” held today in Washington, which will unite millions of Americans across the country to call on our nation’s policymakers to make medical research a national priority.
-
Two Percent Payment Reductions in Medicare Fee-for-Service (FFS) Program Begin on April 1
-
March 29, 2013
-
Because the Congress was unable to reach an agreement on how to reduce the deficit, by law automatic, across-the-board spending cuts known as "sequestration" have been triggered and beginning April 1, 2013, a two percent cut in Medicare provider payments will take effect. Medicare Fee-for-Service (FFS) claims with dates-of-service or dates-of-discharge on or after April 1, will incur a two percent reduction in Medicare payments.
-
ASH Comments to FDA Re: Drug Shortages Task Force and Strategic Plan
-
March 14, 2013
-
The American Society of Hematology (ASH) appreciates the opportunity to submit comments to the Food and Drug Administration (FDA) in response to the FDA Drug Shortages Task Force and Strategic Plan; Request for Comments as announced in the Federal Register (FDA–2013–N–0124) on February 12, 2013.
-
FDA Alerts Health Care Providers of Recall of Anemia Drug Omontys (FDA News)
-
February 25, 2013
-
The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill. The recall is due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients.
< Prev
Next >
Page 1 of 84